SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

University of Michigan Rogel Cancer Center

Status: Enrolling

Conditions: Metastatic Castration-Resistant Prostate Carcinoma

Treatments: Other: Non-Interventional Study

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT07096999

UMCC 2024.070

R01CA289631 (U.S. NIH Grant/Contract)

NCI-2025-01555 (Registry Identifier)

HUM00257753 (Other Identifier)

Details and patient eligibility

About

This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

Enrollment: 60 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• * 177Lu-617 PSMA treatment scheduled for mCRPC

  • Clinically stable as determined by the nuclear medicine clinicians
  • Male
  • ≥ 18 years of age
  • Willing and able to provide informed consent

Exclusion criteria

• Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed

Trial design

60 participants in 1 patient group

Observational

Description:

Patients receive standard care Pluvicto and undergo Lu-177 SPECT/CT scans on study. Patients may also undergo optional 99mTc-SC SPECT/CT scan for bone marrow dosimetry prior to cycle 1. In addition, patients have their medical records reviewed on study.

Treatment:

Other: Non-Interventional Study